Immunovant ends cutaneous lupus program after phase 2 flop

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.